Tirzepatide

Tirzepatide activates both GIP and GLP-1 receptors. It is FDA-approved in the United States under different brand names for type 2 diabetes and, for the weight-management product, chronic weight management and moderate to severe obstructive sleep apnoea in adults with obesity. It is supported by large randomised trials and shares the gastrointestinal side effect profile of the incretin class.

Evidence-first summary of tirzepatide, a dual GIP and GLP-1 receptor agonist: human trial record, FDA approval status, documented risks and open questions.

A dual incretin receptor agonist, approved and extensively trialled.

Key takeaways

What dual agonism means

GIP and GLP-1 are both incretin hormones released after eating, acting through different receptors. Tirzepatide engages both. Whether the added GIP activity explains the effect sizes seen in trials, and exactly how, is still being worked out in the research literature.

The trial base

The development programme includes randomised placebo-controlled and active-comparator trials with pre-specified endpoints, which is why regulators were able to define indications and describe adverse events in detail.

Reading claims carefully

Comparisons between incretin medicines circulate widely online and are frequently drawn from separate trials with different populations and designs. Direct comparison requires head-to-head studies.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

How is tirzepatide different from semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors only. Whether that difference matters for a particular person is a clinical question.

Is it approved for weight loss?

It has weight-related approvals under a separate brand name from its diabetes indication. Indications have expanded since first approval, so check the current FDA record.

Are the side effects different from other GLP-1 medicines?

The gastrointestinal profile is broadly similar across the class, with differences in frequency reported between agents and doses in trials.

Related on Beiing

Sources

  1. FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
  2. Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration
  3. DailyMed - FDA prescribing information search - U.S. National Library of Medicine
  4. FDA - FDA's concerns with unapproved GLP-1 drugs used for weight loss - U.S. Food and Drug Administration
  5. ClinicalTrials.gov - U.S. National Library of Medicine
  6. PubMed - National Library of Medicine - NIH

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.